Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in Adjuvant EGFR Exon 20ins NSCLC
NCT06192849Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- furmonertinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC). Primary endpoint: Disease-Free Survival at 4 years. Started Dec 2023; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Furmonertinib
Furmonertinib 160mg/d
03
Who it enrols
Patients with resected Stage IB-IIIA NSCLC and EGFR exon 20 insertion mutations.
04
Endpoints
Primary
Disease-Free Survival
Secondary
Disease-Free Survival Rate
Overall Survival
Health-Related Quality of Life
Beyond the preview
Go deeper on NCT06192849.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192849.